Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Fig. 1

PARP inhibitors upregulate PD-L1 expression of ovarian cancer cells in vitro. A The IC50 of Niraparib in SKOV3 and UWB1.289 cells. B SKOV3 and UWB1.289 cells were treated with different PARP inhibitors for 48 h and the expression of PD-L1 protein was analyzed by western blotting. C SKOV3 and UWB1.289 cells were transfected with PARP1 siRNA. The PARP1 and PD-L1 expression were analyzed by western blotting. D, E SKOV3 and UWB1.289 cells were treated with different concentrations of Niraparib (0 nM, 500 nM, 1 μM, 5 μM, 10 μM, and 15 μM) and the expression of PD-L1 protein was analyzed by western blotting. F SKOV3 and UWB1.289 cells were treated with different PARP inhibitors for 48 h and the expression of PD-L1 on tumor surface was analyzed by flow cytometry. G UWB1.289 cells were transfected with PARP1 siRNA and the expression of PD-L1 on tumor surface was analyzed by flow cytometry. H Flow cytometry analysis of PD-L1 expression in two cells treated with different concentrations of Niraparib. All experiments were repeated three times. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01

Back to article page